Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date January 14, 2022 · Filed January 18, 2022
Section 16 reporting ended · disclosed 2022-01-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 264,324 |
Reported balance
Holding disclosure · report date 2022-01-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 264,324 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2019 Filed Oct 1, 2019 22:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,157 | $28.63 | $147,644.91 |
DisclosureSEC source: 0001219036-19-000006 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,440 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 22:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,544 | $28.63 | $158,724.72 |
DisclosureSEC source: 0001219036-19-000006 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,597 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 20:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,544 | $29.93 | $165,931.92 |
DisclosureSEC source: 0001219036-19-000004 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,141 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 20:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,214 | $29.93 | $126,125.02 |
DisclosureSEC source: 0001219036-19-000004 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,685 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 20:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-19-000004 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,899 F1 · kind: Consists of performance stock units granted pursuant to the Companys 2017 Employee, Director and Consultant Equity Incentive Plan. Performance stock units initially granted on September 19, 2018, subject to accomplishment of pre-determined financial performance requirements. On September 25, 2019, the Compensation Committee determined the final award amount based on the accomplishment of the applicable financial performance requirements. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 25, 2019, 25% on September 25, 2020, 25% on September 25, 2021, and 25% on September 25, 2022. Read SEC document |
| May 03, 2019 Filed Aug 13, 2019 20:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-19-000002 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,899 Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 12:58 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,157 | $46.00 | $237,222.00 |
DisclosureSEC source: 0001219036-18-000012 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,049 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 12:58 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,544 | $46.00 | $255,024.00 |
DisclosureSEC source: 0001219036-18-000012 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,206 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 18:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,544 | $46.65 | $258,627.60 |
DisclosureSEC source: 0001219036-18-000010 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,750 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 16:11 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-18-000008 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,294 F1 · kind: Consists of performance stock units granted pursuant to the Companys 2010 Employee, Director and Consultant Equity Incentive Plan. Performance stock units initially granted on September 17, 2017, subject to accomplishment of pre-determined financial performance requirements. On September 19, 2018, the Compensation Committee determined the final award amount based on the accomplishment of the applicable financial performance requirements. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 25, 2018, 25% on September 25, 2019, 25% on September 25, 2020, and 25% on September 25, 2021. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 6,515 | $46.35 | $301,970.25 |
DisclosureSEC source: 0001219036-18-000006 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,294 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 46,139 | $0.00 Strike: $30.34 | $0.00 |
DisclosureSEC source: 0001219036-18-000004 · edgardoc.xml · derivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,139 shares Expires 2019-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,861 | $0.00 Strike: $30.34 | $0.00 |
DisclosureSEC source: 0001219036-18-000004 · edgardoc.xml · derivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,861 shares Expires 2019-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,861 | $43.34 | $167,338.83 |
DisclosureSEC source: 0001219036-18-000004 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,809 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 3,861 | $30.34 | $117,142.74 |
DisclosureSEC source: 0001219036-18-000004 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 46,139 | $43.34 | $1,999,701.17 |
DisclosureSEC source: 0001219036-18-000004 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,809 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 46,139 | $30.34 | $1,399,857.26 |
DisclosureSEC source: 0001219036-18-000004 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 57,654 | $0.00 Strike: $30.12 | $0.00 |
DisclosureSEC source: 0001219036-18-000002 · edgardoc.xml · derivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,654 shares Expires 2019-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,346 | $0.00 Strike: $30.12 | $0.00 |
DisclosureSEC source: 0001219036-18-000002 · edgardoc.xml · derivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,346 shares Expires 2019-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 2,346 | $40.12 | $94,121.52 |
DisclosureSEC source: 0001219036-18-000002 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,809 Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 2,346 | $30.12 | $70,661.52 |
DisclosureSEC source: 0001219036-18-000002 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 57,654 | $40.12 | $2,313,078.48 |
DisclosureSEC source: 0001219036-18-000002 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,809 Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 57,654 | $30.12 | $1,736,538.48 |
DisclosureSEC source: 0001219036-18-000002 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,459 | $36.18 | $197,506.62 |
DisclosureSEC source: 0001219036-17-000006 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,809 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,869 | $36.18 | $212,340.42 |
DisclosureSEC source: 0001219036-17-000006 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,268 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 17, 2017 Filed Sep 19, 2017 21:28 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 6,897 | $33.05 | $227,945.85 |
DisclosureSEC source: 0001219036-17-000004 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,137 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:52 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-17-000002 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,034 F1 · kind: Consists of performance stock units granted pursuant to the Company?s 2010 Employee, Director and Consultant Equity Incentive Plan. Performance stock units initially granted on September 14, 2016, subject to accomplishment of pre-determined financial performance requirements. On September 13, 2017, the Compensation Committee determined the final award amount based on the accomplishment of the applicable financial performance requirements. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 30, 2017, 25% on September 30, 2018, 25% on September 30, 2019, and 25% on September 30, 2020. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 21:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,459 | $20.58 | $112,346.22 |
DisclosureSEC source: 0001219036-16-000014 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,034 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 17, 2016 Filed Sep 20, 2016 12:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,752 | $20.92 | $99,411.84 |
DisclosureSEC source: 0001219036-16-000012 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,493 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 17:59 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 46,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-16-000010 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,245 F1 · kind: Consists of performance stock units granted pursuant to the Company?s 2010 Employee, Director and Consultant Equity Incentive Plan. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 30, 2016, 25% on September 30, 2017, 25% on September 30, 2018, and 25% on September 30, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.